6316-09-2

Usage

General Description

6-Chloro-N^4^-ethylpyrimidine-2,4-diamine is a chemical compound with the molecular formula C7H10ClN5. It is a derivative of pyrimidine and contains a chlorine atom and an ethyl group. 6-Chloro-N~4~-ethylpyrimidine-2,4-diamine is commonly used in the synthesis of pharmaceuticals and agrochemicals. It is also known to exhibit antimicrobial and antifungal properties. 6-Chloro-N^4^-ethylpyrimidine-2,4-diamine is an important building block in organic synthesis and has potential applications in the development of new drugs and agricultural products.

InChI:InChI=1/C18H14Cl2N2O3/c1-10-3-6-12(9-14(10)19)22-17(23)15(20)16(18(22)24)21-11-4-7-13(25-2)8-5-11/h3-9,21H,1-2H3

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 75-04-7 ethylamine 
• 557-66-4 ethanamine hydrochloride 

Downstream Products

• 1227909-50-3 4-[2-amino-6-(ethylamino)-4-pyrimidinyl]-2-fluorobenzonitrile trifluoroacetate 
• 164525-11-5 2-amino-6-ethylaminopyrimidin-4(3H)-one 

Relevant academic research and scientific papers

Heterocyclic compounds as well as preparation method and application thereof

The invention belongs to the field of medicines and particularly relates to heterocyclic compounds with the structural characteristics shown in formula (I) or pharmaceutically acceptable salts, a preparation method and an application of the heterocyclic compounds as a nucleotide oxidative damage repairase MTH1 inhibitor. Pharmacological experiment results indicate that the compounds have significant inhabitation effects on the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors

Phosphoinositide-dependent protein kinase-1(PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated across all cancers, a selective inhibitor of PDK1 might have utility as an anticancer agent. Herein we describe our lead optimization of compound 1 toward highly potent and selective PDK1 inhibitors via a structure-based design strategy. The most potent and selective inhibitors demonstrated submicromolar activity as measured by inhibition of phosphorylation of PDK1 substrates as well as antiproliferative activity against a subset of AML cell lines. In addition, reduction of phosphorylation of PDK1 substrates was demonstrated in vivo in mice bearing OCl-AML2 xenografts. These observations demonstrate the utility of these molecules as tools to further delineate the biology of PDK1 and the potential pharmacological uses of a PDK1 inhibitor.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Pyrimidine derivatives

A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.

Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated

Composition for slowing down the loss of hair and for inducing and stimulating its growth, comprising a compound of formula: STR1 in which: R1 and R2 denote H or an alkyl and do not simultaneously denote H; R3 and R4 denote H, an alkyl or a heterocyclic ring with the nitrogen in position 6 and do not simultaneously denote H; X denotes H or a halogen; Y denotes O or OSO3 ; and their addition salts of physiologically acceptable acids.